Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 205,232,062 papers from all fields of science
Search
Sign In
Create Free Account
Advair Diskus
A dry powdered inhaler formulation of fluticasone-salmeterol drug combination.
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
1 relation
Broader (1)
Fluticasone Propionate, Salmeterol Xinafoate Drug Combination
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Wixela Inhub: Dosing Performance In Vitro and Inhaled Flow Rates in Healthy Subjects and Patients Compared with Advair Diskus
A. Cooper
,
J. Parker
,
M. Berry
,
R. Wallace
,
J. Ward
,
R. Allan
Journal of aerosol medicine and pulmonary drug…
2020
Corpus ID: 218760050
Background: Wixela™ Inhub™ is a fluticasone propionate/salmeterol dry powder inhaler developed as a generic equivalent of Advair…
Expand
2019
2019
Clinical Bioequivalence of Wixela Inhub and Advair Diskus in Adults With Asthma
Dik Ng
,
E. Kerwin
,
+4 authors
R. Allan
Journal of aerosol medicine and pulmonary drug…
2019
Corpus ID: 204834004
Background: Wixela® Inhub® is a dry powder inhaler approved as a generic equivalent to Advair® Diskus® (fluticasone propionate…
Expand
2017
2017
Between‐Batch Pharmacokinetic Variability Inflates Type I Error Rate in Conventional Bioequivalence Trials: A Randomized Advair Diskus Clinical Trial
E. Burmeister Getz
,
K. Carroll
,
J. Mielke
,
L. Benet
,
B. Jones
Clinical pharmacology and therapeutics
2017
Corpus ID: 6733944
We previously demonstrated pharmacokinetic differences among manufacturing batches of a US Food and Drug Administration (FDA…
Expand
2017
2017
Clinical Bioequivalence of OT329 SOLIS and ADVAIR DISKUS in Adults with Asthma
M. Longphre
,
E. B. Getz
,
R. Fuller
Annals of the American Thoracic Society
2017
Corpus ID: 3615377
Rationale: OT329 SOLIS is a generic candidate for the branded asthma treatment, ADVAIR DISKUS (fluticasone propionate/salmeterol…
Expand
Highly Cited
2011
Highly Cited
2011
Assessing the safety of adding LABAs to inhaled corticosteroids for treating asthma.
B. Chowdhury
,
S. Seymour
,
Mark S Levenson
The New England journal of medicine
2011
Corpus ID: 205107496
The FDA has issued a requirement for manufacturers of long-acting beta-agonists (LABAs) marketed for asthma to conduct controlled…
Expand
Review
2006
Review
2006
Long-acting beta-agonists role in asthma management.
J. Donohue
,
L. Fromer
The Journal of family practice
2006
Corpus ID: 23786187
The LABAs have played an important role in the management of asthma over the past decade. They are of clear benefit in reducing…
Expand
Highly Cited
2005
Highly Cited
2005
A Comparison of Brand-Name Drug Prices between Canadian-Based Internet Pharmacies and Major U.S. Drug Chain Pharmacies
B. Quon
,
R. Firszt
,
M. Eisenberg
Annals of Internal Medicine
2005
Corpus ID: 36638930
Context Although many Americans use the Internet to purchase drugs from Canadian pharmacies, no study has systematically…
Expand
2004
2004
Adherence logger for a dry powder inhaler: a new device for medical adherence research.
D. Bogen
,
A. Apter
The Journal of allergy and clinical immunology
2004
Corpus ID: 44974864
2002
2002
Step-down therapy with low-dose fluticasone-salmeterol combination or medium-dose hydrofluoroalkane 134a-beclomethasone alone.
S. Fowler
,
G. Currie
,
B. Lipworth
The Journal of allergy and clinical immunology
2002
Corpus ID: 32877606
BACKGROUND Options for step-down therapy include use of inhaled corticosteroids alone or in combination with a long-acting beta2…
Expand
Review
2001
Review
2001
Advair: combination treatment with fluticasone propionate/salmeterol in the treatment of asthma.
H. Nelson
The Journal of allergy and clinical immunology
2001
Corpus ID: 26917213
Several classes of medications are available for the treatment of asthma, and often they must be taken concurrently to achieve…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
,
Terms of Service
, and
Dataset License
ACCEPT & CONTINUE